A Word From Our Sponsor: bluebird bio
Thank you to bluebird bio for their generous support of our 49th Annual National Convention! How can you help to spark change... Continue Reading
SCDAA launches clinical trial finder
HANOVER, Md.—The Sickle Cell Disease Association of America launched a sickle cell disease clinical trial finder, a centralized, simple-to-navigate website to... Continue Reading
MARAC Advisory Statement Update About COVID-19 Vaccines
September 24, 2021 — News about COVID-19 continues to move quickly as we weather the pandemic. The Sickle Cell Disease Association... Continue Reading
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to deliver keynote SOUTH SAN FRANCISCO, Calif., and BALTIMORE – September... Continue Reading
MARAC Issues Updated COVID-19 Guidance
August 26, 2021 – The Sickle Cell Disease Association of America Medical and Research Advisory Committee has released two statements with... Continue Reading
HCPLive® Announces Partnership With Sickle Cell Disease Association of America (SCDAA)
HCPLive® Announces Partnership With Sickle Cell Disease Association of America (SCDAA) SCDAA’s mission is to advocate for people affected by sickle... Continue Reading
SCDAA names government relations manager
Sickle Cell Disease Association of America named John Otsuki as government relations manager. Otsuki brings experience in regulatory and legislative affairs,... Continue Reading
Sickle Cell Disease Association of America announces new teen ambassador
Sickle Cell Disease Association of America (SCDAA) named 14-year-old Ayana Lee Johnson the 2021-2023 SCDAA National Teen Ambassador. She was selected... Continue Reading
The Kidney Cancer Association and SCDAA launch KNOW & TELL
New campaign to raise awareness about connection between sickle cell trait and deadly form of kidney cancer. The Kidney Cancer Association... Continue Reading
The Hibiscus Study is Enrolling Volunteers
Study Title: An adaptive, randomized, placebo-controlled, double-blind, multi-center study of oral FT-4202, a pyruvate kinase activator, in patients with sickle cell... Continue Reading